Drugs / Xaluritamig
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07493512 | Apr 2026 → Jan 2028 expected | castration-resistant prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07297979 | Apr 2026 → May 2030 expected | Ewing sarcoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07140900 | Oct 2025 → Mar 2028 expected | metastatic prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT06613100 | Nov 2024 → Jan 2027 expected | prostate cancer | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT06555796 | Sep 2024 → Oct 2026 expected | prostate cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04221542 | Mar 2020 → Mar 2030 expected | prostate cancer | Amgen | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07213674 | Nov 2025 → Jan 2030 expected | prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06691984 | Dec 2024 → Jan 2029 expected | castration-resistant prostate carcinoma | Amgen | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xaluritamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07140900 ↗ |
| Known as | AMG 509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04221542 ↗ |
| Route | Intravenous | “AMG 509 administered as an IV infusion” NCT04221542 ↗ |